Skip to main content

NIH s Chem Genomics Center to Use Invitrogen Tools in Screening Program

NEW YORK, March 7 (GenomeWeb News) - The National Institutes of Health's ChemicalGenomicsCenter will use Invitrogen's CellSensor cell lines and GeneBLAzer beta-lactamase reporter gene technology to identify compounds that modulate disease-relevant signaling pathways, the company said today.

 

The NCGC will use the assay technology with quantitative high-throughput screening program, Invitrogen said, and all of the screening data from the collaboration will be deposited in PubChem.

 

As these new assays generate compounds of interest, Invitrogen and the NCGC may agree to work together to identify the protein targets they affect through the use of additional Invitrogen technologies such as Stealth RNAi and Protoarray Human Protein Microarrays, Invitrogen said.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.